 Salix Pharmaceuticals Ltd and the Italian parent company of drug maker Cosmo Technologies Ltd said Friday they had terminated a previously announced  billion merger agreementa deal that had been structured as a socalled inversion Those deals have come under increased scrutiny in Washington and elsewhere Raleigh NCbased Salixs move to scrap the agreement represents one of the first dealmaking retreats in the wake of new rules implemented last month by the US Treasury to make inversions less attractive